Exelixis' Zanzalintinib Approval Hinge on December 2026 FDA Decision Fuels Catalyst-Driven Overweight Trade

The core investment thesis for Exelixis now hinges on a single, high-stakes regulatory milestone. The FDA has accepted the company's New Drug Application for zanzalintinib in combination with atezolizumab, with a target action date of December 3, 2026. This is the critical catalyst that could validate Exelixis's pipeline strategy and justify a portfolio overweight. The application is based on the Phase 3 STELLAR-303 trial, which demonstrated a statistically significant improvement in overall survival versus regorafenib in the intention-to-treat population of previously treated metastatic colorectal cancer patients. In a setting of high unmet need, where outcomes remain poor and liver metastases are common, this data positions zanzalintinib as a potential best-in-class therapy.

The market is already pricing in this anticipation. The stock has shown clear positive momentum, with a 5.3% gain over the past 20 days and an 8.2% gain over 120 days. This reflects institutional flow betting on a successful December approval. The setup is a classic catalyst-driven trade: a promising clinical profile meets a defined regulatory timeline, creating a binary event with significant upside if approved. The bottom line is that a positive decision next December would be a major validation of Exelixis's R&D execution and could dramatically alter the company's growth trajectory and valuation.

Yet, the ultimate impact remains binary and hinges entirely on the December outcome. The approval is not guaranteed, and the stock's recent gains have already captured a significant portion of the potential upside. For portfolio construction, this creates a high-conviction, high-risk position. It is a conviction buy for those willing to accept the regulatory uncertainty, but it is not a low-volatility holding. The December target date provides a clear timeline for reassessment, making this a tactical, catalyst-driven overweight rather than a core, quality-factor holding.

Financial Health and the Cabozantinib Foundation

The institutional case for Exelixis rests on a clear duality: a high-risk, high-reward bet on zanzalintinib is underwritten by the robust financial health of its commercial engine. The cabozantinib franchise provides the essential bedrock of cash flow and balance sheet strength that funds the pipeline and mitigates risk during the regulatory wait. For portfolio construction, this is the quality factor that makes the catalyst trade palatable.

Commercially, cabozantinib remains a powerful cash-generating asset. The franchise delivered $2.123 billion in U.S. net product revenues for fiscal 2025, a significant year-over-year increase that underscores sustained demand in renal cell carcinoma and neuroendocrine tumors. Management is guiding for continued growth, projecting 2026 net product revenues of $2.325-$2.425 billion. This represents a solid 10% growth trajectory from the prior year, providing a reliable stream of operating cash that does not rely on the zanzalintinib outcome. The company is actively investing in this growth, having expedited the buildout of its gastrointestinal sales team to prepare for future indications.

This financial foundation supports a prudent capital allocation strategy. The company's valuation reflects this cash-generating reality. With a forward P/E of 14.2 and an EV/EBITDA of 11.2, the stock trades at a multiple that prices in current operations but does not yet fully reflect the potential blockbuster upside of zanzalintinib. This creates a structural tailwind: the core business provides a margin of safety and funding for the high-risk bet, while the valuation leaves room for a multiple re-rating if the December catalyst is positive.

In essence, cabozantinib is the institutional-grade holding that makes the zanzalintinib speculation a viable portfolio allocation. It transforms a binary, speculative event into a managed-risk investment. The cash flow from the franchise reduces the urgency for dilutive financing, preserves balance sheet flexibility, and allows the company to fund its R&D pipeline through the catalyst window. For a portfolio manager, this is the critical context: the high-conviction overweight is supported by a quality, cash-flowing asset that provides both the runway and the risk buffer.

Portfolio Construction and Risk-Adjusted Return Profile

From a portfolio construction perspective, Exelixis represents a high-conviction, high-risk position that demands a clear understanding of its payoff structure. The investment case is binary, but the potential reward is substantial, anchored by the strategic importance of zanzalintinib as a potential second commercial franchise. Management itself frames 2026 as a year of progress toward building this new pillar, explicitly stating the goal is to build a potential second commercial franchise with zanzalintinib. This is critical for reducing the portfolio's reliance on the single, albeit robust, cabozantinib engine. A successful approval would diversify revenue streams and fundamentally alter the company's growth trajectory, moving it from a single-product story to a multi-franchise oncology platform.

Beyond the immediate catalyst, the pipeline provides a layer of long-term growth support that mitigates the risk of a single asset dependency. The company is not betting everything on zanzalintinib; it is actively advancing its earlier-stage assets. In March 2025, Exelixis presented preclinical data for four pipeline molecules, highlighting their potential as best- or first-in-class therapies for advanced solid tumors. This diversification effort, focused on small molecules and biotherapeutics, supports a longer-term growth narrative that extends beyond the December 2026 catalyst. It provides a structural tailwind for the portfolio, suggesting the company is building a sustainable pipeline beyond the next binary event.

The primary risk, therefore, is the binary regulatory outcome in December 2026. A positive decision would validate the high bar set by the Phase 3 STELLAR-303 data and open a clear path to higher valuation multiples, as the market would begin pricing in a second commercial franchise. Conversely, a rejection would likely trigger a significant re-rating, as the high-risk, high-reward bet would fail. The stock's recent momentum, including a 5.3% gain over the past 20 days, reflects the market's bet on approval, meaning much of the potential upside is already priced in. For portfolio managers, this creates a classic risk-adjusted return profile: a high-conviction overweight with a defined timeline for reassessment. It is a tactical allocation that requires conviction in the clinical data and the company's execution, balanced against the clear downside of a regulatory setback.

Catalysts, Scenarios, and What to Watch

For portfolio managers, the institutional case for Exelixis now requires a disciplined monitoring framework. The investment thesis is binary and time-bound, anchored by a single regulatory catalyst. The checklist for assessing the stock's trajectory is clear: watch the December 2026 decision, track the core business's execution, and gauge the long-term durability of the cash engine.

The paramount near-term event is the FDA's decision on the zanzalintinib NDA. The agency has assigned a target action date of December 3, 2026. This is the definitive binary event that will validate or invalidate the high-conviction overweight. The Phase 3 STELLAR-303 data showed a statistically significant improvement in overall survival versus regorafenib, but the final decision rests with the agency. A positive ruling would trigger a re-rating, unlocking the potential for a second commercial franchise. A rejection would likely cause a sharp decline, as the high-risk bet fails. This is the primary catalyst to monitor.

Parallel to this binary event is the execution of the core business. The cabozantinib franchise must hit its 2026 net product revenues guidance of $2.325-$2.425 billion to confirm the underlying cash engine remains robust. This revenue stream funds the pipeline and provides a margin of safety. Any deviation from this guidance would signal commercial vulnerability and could pressure the stock independently of the zanzalintinib outcome. Management's focus on expanding the gastrointestinal sales force indicates preparation for future indications, but consistent top-line performance is non-negotiable for maintaining the quality factor.

Finally, the long-term durability of the cabozantinib franchise must be assessed. The recent final five-year results from the CheckMate-9ER trial demonstrated sustained survival benefits with the cabozantinib/nivolumab combination in renal cell carcinoma. This long-term efficacy data is critical for supporting the franchise's premium positioning and pricing power. Watch for future updates from this and other combination studies, as they will inform the longevity of the cash flow that underpins the entire investment thesis.

In practice, this creates a three-pronged monitoring framework. The December 2026 date is the ultimate trigger. Quarterly cabozantinib revenue reports are the near-term checkpoints for stability. And long-term efficacy data from ongoing trials are the signals for franchise durability. For a portfolio, this is a tactical allocation that demands vigilance on all three fronts.